41 results about "Surgical resection" patented technology

The present disclosure provides methods for treating, reducing the severity of, inhibiting the growth of a tumor, or inducing necrosis of a tumor, wherein the method includes selecting a patient with cancer (e.g., liver cancer, lung cancer, or head and neck cancer) in need thereof and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or abioequivalent thereof) as neoadjuvant therapy followed by surgical resection and optional administration of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or a bioequivalent thereof) as post-surgery adjuvant therapy. In certain embodiments, the liver cancer is hepatocellular carcinoma (HCC), the lung cancer is non-small cell lung cancer (NSCLC), or the head and neck cancer is head and neck squamous cell carcinoma (HNSCC).

A method for a method for treatment of cholangiocarcinoma (CCA) with cold atmospheric plasma and Folfirinox. The method includes treating a patient having CCA with a low dosage FOLFIRINOX regimen, for example, 6.73 nM, giving the patient the low-dosage FOLFIRINOX regimen pre-operatively, surgically removing the cancerous tumor from the patient, continuing the low-dosage FOLFIRINOX treatment regimen intra-operatively, applying cold atmospheric plasma to the surgical margins surrounding the area in the patient from which the tumor was removed, and continuing the FOLFIRINOX post-operatively.

Indivi dualized neoantigen vaccines, as well as methods for their use in subjects to treat urothelial orbladder cancer are provided. In some embodiments, individualized neoantigen vaccines are used with an immune checkpoint inhibitor and optionally enfortumab vedotin to treat a urothelial or bladder cancer after surgical resection. Prior to surgical resection, in some embodiments, the subject is administered a neoadjuvant therapy comprising an immune checkpoint inhibitor, individualized neoantigen vaccines, and, optionally, enfortumab vedotin.

The invention discloses sodium alginate hydrogel of a chimeric antigen receptor NK cell for expressing catalase and application of the sodium alginate hydrogel. The hydrogel is formed by mixing endogenous calcium ion reactive hydrogel composed of HER1-CAR-CAT-NK and sodium alginate. After the hydrogel disclosed by the invention is injected into an operation excision part, HER1-CAR-CAT-NK cells are decomposed into oxygen by catalyzing main active oxygen (hydrogen peroxide) in a tumor, so that the tolerance of the cells to high-level oxidative stress and hypoxia in the tumor is improved, and the hydrogel shows obviously enhanced durability and effect functions in triple negative breast cancer, and therefore, the hydrogel can be used for preparing a medicine for treating the triple negative breast cancer. The local cell therapy not only can inhibit the growth of local primary residual tumors, but also can stimulate the whole-body anti-tumor activity and inhibit the growth of distant tumors. According to the present invention, the tumor oxidative stress and the anoxic microenvironment are remodeled through the ALG of HER1-CAR-CAT-NK so as to inhibit the postoperative recurrence of TNBC;

This disclosure provides methods for treating tumors, reducing tumor severity, inhibiting tumor growth, or inducing tumor necrosis, wherein the methods include: selecting a patient with cancer (e.g., liver cancer, lung cancer, or head and neck cancer) in need of treatment and administering neoadjuvant therapy to the patient in a combination of a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cimiprimab or its bioequivalent) and radiation therapy (e.g., SBRT) or an anti-LAG-3 antibody (e.g., fenpromab), followed by surgical resection and optionally administration of a programmed death 1 (PD-1) inhibitor (e.g., cimiprimab or its bioequivalent) as postoperative adjuvant therapy. In some embodiments, the cancer is liver cancer, such as hepatocellular carcinoma (HCC).

We disclose a composition, comprising a compound, comprising a melanin precursor that spontaneously synthesizes a melanin when in free form in vivo, and a peptide directly covalently bonded to or indirectly linked to the melanin precursor, wherein the direct covalent bond or indirect link of the peptide to the melanin precursor blocks spontaneous synthesis of the melanin in vivo in the absence of protease activity. We also disclose methods of tumor imaging, tumor detection, diagnosis, and treatment, including methods comprising administering, to a patient suffering from a tumor, the composition; and either surgically resecting the tumor or thermally ablating the tumor, wherein the surgical resection is guided at least in part by contrast imparted by, or the thermally ablating targets cells containing, the melanin, wherein the melanin is spontaneously synthesized in the tumor after administering the composition.

The present disclosure relates generally to cancer immunotherapies and, more particularly, to a polymer matrix delivery system for delivering a cancer adjuvant, especially for enhanced immunotherapy. More particularly, the disclosure relates to a polymer matrix delivery system for delivering a cancer adjuvant, comprising a biodegradable polymer; a cancer adjuvant; optionally, an immunomodulatory inorganic ion; and, a bulking agent, wherein the bulking agent is not a protein. An implant comprising the polymer matrix delivery system is also provided. A method of treating a solid tumor or the potential recurrence of a solid tumor comprising injecting the implant into the solid tumor or at a site of surgical resection of a solid tumor is also described.

According to the radioactive hydrogel and the preparation method and application thereof and the radioactive tumor treatment application, chitosan serves as a matrix and is crosslinked with genipin to construct a three-dimensional network, and stable loading and slow release of radionuclides can be synchronously achieved; the self-antibacterial and adhesion characteristics of the patch can reduce the infection risk and ensure the fixation of the patch, so that a safe, effective and easy-to-operate local treatment platform is provided, the prepared patch can be directly placed on a tumor bed after resection in an operation, beta or alpha rays released by radionuclides accurately and continuously act on an area where tumor cells are most likely to remain, and the effect of treating the tumor cells is achieved. Different from traditional external radiation radiotherapy, the hydrogel can continuously release radiation with a low dosage rate. The mode has a stronger biological effect (such as inhibition of reproliferation) on tumor cells, the radiosensitivity difference of different cell periods and time phases can be overcome, the killing effect is more thorough, and chitosan is proved to have certain antibacterial activity, tumor cell growth inhibition activity and immunomodulatory activity. A synergistic effect can be generated with radionuclide, and a microenvironment which is not beneficial to survival and relapse of tumor cells is constructed together with the radionuclide.

A method, system, medium, and implementations for computer-aided preoperative surgical planning are described. Input data acquired with respect to a part of a patient is received by the system. The part corresponds to an organ, e.g., lung, of the patient to be operated on and includes one or more lesions to be removed during an operation. Then, an anatomic 3D model of the part of the patient is generated. Based on the generated anatomic 3D model, a preoperative plan for linear-cutting stapler resection of the one or more lesions from the organ to be carried out during the operation is obtained. The stapler cartridge size and the staple length are estimated based on the preoperative plan. Further, the resection based on the preoperative plan is visualized.

The application relates to a surgical rotary cutting system, comprising a rotary puncture device and a cutter device; the rotary puncture device comprises a puncture rod and a tissue fixing head arranged at one end of the puncture rod, the tissue fixing head is used for fixedly connecting with target tissue, and the puncture rod is used for driving the target tissue to rotate relative to the cutter device through the tissue fixing head; the cutter device comprises a cutting head, and the cutting head is used for cutting the target tissue into a continuous long strip structure. When the target tissue rotates, the cutter device which keeps the position unchanged can continuously cut the target tissue, so that the target tissue is cut into the continuous long strip structure. Finally, the long strip target tissue can be clamped to the outside of the abdominal wall at any position of the long strip structure through clamps, so that the target tissue does not need to be repeatedly clamped by the clamps for multiple times, and the operation is simple and efficient.

The invention discloses a method for constructing a liver injury animal model, which comprises the following steps: (a) providing a model animal, and completely anesthetizing the model animal; (b) the liver of the model animal is taken out, and the surgical resection proportion is determined; and (c) fixing the liver part needing to be cut by using a surgical suture line, and performing liver cutting. According to the method disclosed by the invention, the liver injury mouse model can be more efficiently constructed, and liver injury proportions required by different liver injury models can be met.

The invention belongs to the technical field of small-molecule fluorescent probes, and discloses a high-affinity selective mutant isocitrate dehydrogenase 1 fluorescent probe and application thereof, the structural formula of the fluorescent probe is as shown in formula I, ; in the formula, X1 is a carbon atom or an oxygen atom; x2 is a halide ion or a tetrafluoroboric acid ion; n is 0-5; m is 0-2; r1 and R2 are hydrogen, methyl or ethyl; r3 is an electron donor substituent; r < 4 > is 4-dimethylamino phenyl or 6-dimethylamino naphthyl. The fluorescent probe provided by the invention can accurately identify glioma cells carrying mutant isocitrate dehydrogenase 1 and indicate tumor boundaries, can be used as a targeted fluorescent imaging agent, and has a huge potential of being applied to glioma fluorescence-guided resection.

Methods of producing an incised tissue are presented. The methods may include: contacting a portion of a tissue grasping implement of a first robotic manipulator with a tissue to produce contacted tissue, grasping the contacted tissue using the tissue grasping implement of the first robotic manipulator to produce grasped tissue, and creating an incision in the grasped tissue using a surgical cutting implement of a second robotic manipulator to produce the incised tissue. Additional methods as well as related systems and computer readable media are also presented.

This invention relates to an epileptogenic nodule localization system based on MRI radiomics, belonging to the field of medical informatics. The system includes an image acquisition module, a delineation module, an extraction module, an analysis module, a modeling module, and an optimization module. It extracts radiomics features from the epileptogenic and non-epileptic nodule lesion regions of original MRI T2-Flair images of TSC patients. The preliminary radiomics features are preprocessed, optimized, analyzed, and screened to obtain differential radiomics features between epileptogenic and non-epileptic nodules. A predictive model is established using machine learning algorithms on the obtained differential radiomics features to calculate the radiomics feature score for each lesion, identifying epileptogenic nodules from cortical epileptogenic nodules. This achieves the goal of non-invasive identification of epileptogenic foci in TSC patients, assisting in clinical diagnosis and personalized surgical planning, and enabling precise treatment and surgical resection of epileptogenic foci in TSC patients.

The present disclosure relates to methods for treating a tumor or inhibiting tumor proliferation comprising administering to a cancer patient in need thereof a therapeutically effective amount of a programmed death ligand 1 (PD-L1) inhibitor (e.g., an anti-PD-L1 antibody) as a neoadjuvant therapy followed by surgical resection. In particular, the present disclosure relates to methods for administering a PD-L1 inhibitor as a pre-operative therapy to a patient suffering from resectable upper gastrointestinal cancer (e.g., resectable localized gastric, esophageal or liver cancer). Administration of a PD-L1 inhibitor, in particular an anti-PD-L1 antibody, has proved to exhibit an excellent therapeutic effect as a pre-operative therapy for patients suffering from resectable localized gastric, esophageal and liver cancer.

w The invention discloses a detection method for predicting efficacy and prognosis of immunotherapy for small cell lung cancer based on ATAD2 expression, and relates to the technical fields of molecular biology and cancer treatment. The method comprises the following steps: extracting a tumor tissue sample of a small cell lung cancer patient through surgical resection; Detecting the tumor tissue sample to obtain ATAD2 expression level, wherein the detection adopts an immunohistochemical staining method. According to the invention, the expression level of ATAD2 in tumor tissues of small cell lung cancer is quantitatively evaluated by immunohistochemical detection technology, and the molecular marker information is systematically correlated with the clinical and pathological characteristics of patients by combining Cox regression analysis and Logistic regression analysis, so that the comprehensive prediction of immunotherapy efficacy and patient survival time is realized.

The invention belongs to the technical field of immune cell culture, and particularly relates to a tumor infiltration lymphocyte amplification composition, a kit and an amplification method thereof. The invention provides the tumor infiltration lymphocyte amplification composition aiming at a trace amount of tumor tissue, namely a tumor puncture sample, the tumor infiltration lymphocyte amplification composition is used for amplifying the tumor infiltration lymphocyte, the problem that the tumor tissue sample size required by the tumor infiltration lymphocyte is large is solved, and the tumor infiltration lymphocyte amplification composition is suitable for a patient who cannot receive the tumor tissue obtained by surgical excision. Besides, by optimizing the antibody stimulant combination and the working concentration and establishing the technological process for amplifying the tumor infiltration lymphocytes based on the puncture sample, the dryness of the tumor infiltration lymphocytes obtained through amplification is maintained, the lethality is improved, and therefore the anti-tumor curative effect after the tumor infiltration lymphocytes are infused back into the body is guaranteed.

The invention discloses a glioma operation boundary identification marker and application thereof. The invention confirms that SERPINA3 can be used as a marker for identifying a glioma invasion boundary for the first time, can effectively assist operation planning and tumor excision before or during glioma operation, improves the accuracy of operation excision, provides an effective molecular tool for clinical diagnosis and treatment of glioma, and has a remarkable application prospect.

A surgical resection device may include a handle, a first blade tip, and a second blade tip stacked on the first blade tip and configured to resect bone in conjunction with the first blade tip. A surgical resection device may include a blade body, stationary with respect to the handle, moveably interfaced to the first blade tip and second blade tip, and dimensionally configured to enter a resection formed by the first and second blade tip. A surgical resection device may include one or more actuators located within the handle and configured to oscillate the first blade tip and the second blade tip, wherein when the first blade tip is at a first apex position, the second blade tip is at a second apex position, and wherein when the first blade tip is at the second apex position, the second blade tip is at the first apex position.

The invention discloses application of radix trichosanthis polysaccharide to preparation of a medicine for regulating immunity and inhibiting postoperative recurrence of colorectal cancer. The radix trichosanthis polysaccharide is found to be capable of promoting M2 phenotype macrophages to be polarized to M1 phenotype, and has an immunoregulation function; meanwhile, proliferation of peripheral blood lymphocytes and spleen lymphocytes is promoted, the proportion of CD4 +, CD8 + and NK cells is increased, and the effect of enhancing immunity is achieved. Furthermore, the hydrogel CMOT prepared by taking the radix trichosanthis polysaccharide as the raw material has good biocompatibility in vitro and in vivo and has the qualified characteristic of hydrogel, and the CMOT hydrogel is found to have the effect of inhibiting the recurrence of the colorectal cancer when being applied to the resection part of the mouse colorectal cancer operation. Therefore, the radix trichosanthis polysaccharide hydrogel has the potential of becoming a postoperative wound dressing after cancer resection.

The application discloses a brain network analysis method based on step-by-step information flow and de-redundancy, and belongs to the field of image analysis; solves the problems that a simple network building mode cannot reflect the information flow propagation process between specific regions at different levels, and information redundancy caused by the repeated existence of some edges in different high-order adjacency matrices, etc. The interaction between electrodes at the connection level is mainly captured through a step-by-step process, and the redundant information between matrices of different orders is eliminated by using a de-redundancy module. Finally, the epilepsy propagation path is successfully captured, thereby providing a reference value for surgical resection of intractable epilepsy patients.

The invention relates to a structural tube called 'H drainage tube for biliary tract drainage', and aims to establish natural drainage of bile from the bile duct to the small intestine. An H drainage tube is an internal biliary drainage tube and plays a crucial role in biliary drainage under the condition of malignant biliary obstruction such as pancreatic head cancer, spent testis papilla, duodenum, bile duct cancer and hepatocellular carcinoma, and due to local advanced diseases and metastasis, the Hdrainage tube and the H drainage tube are not suitable for curing surgery. The H drainage tube plays an important role in the case of anatomical structure changes, gastric outlet obstruction and previous gastric bypass surgery. Unlike existing palliative methods for malignant biliary obstruction, H drainage tubes provide liver function recovery and nutritional condition improvement, reduce systemic endotoxemia and enhance the likelihood of immune response by internal drainage and recovery of bile flow into the enteric cavity. The H drainage tube has the capabilities of flushing, dredging under the condition of obstruction, collecting bile samples and performing contrast imaging on bile ducts. Thus, it can also be used in temporary methods intended to improve the overall condition of a patient and to prepare for surgical resection or performing palliative radiotherapy or chemotherapy. The H drainage tube can also be applied to patients with highly non-resectable lesions of the common hepatic duct and is intended for biliary tract drainage and guiding bile into the small intestine. Postoperative complications are minimized due to the design and method of placement of the H drainage tube. It significantly improves the quality of life of a patient, which is the main objective of palliative treatment. It is important to the patient that it has a positive psychological impact, without external drainage and without the need to use bags for biliary tract contents, thereby achieving better quality of life.

Provided herein are compositions and methods for treating a glioblastoma in a patient after surgical resection, radiation therapy and chemotherapy comprising administering to the patient a therapeutically effective amount of an intravenous liposomal curcumin or curcuminoids to a human subject in need thereof after surgical resection of the glioblastoma a dosing regimen comprising the therapeutically effective amount of the liposomal curcumin or curcuminoids of at least 300 mg / m2 over 8 hours or less, and wherein a treatment cycle is for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 consecutive weeks.

The invention discloses a construction method of a lung organ model based on a COPD patient source, relates to the technical field of biomedical model construction, and efficiently constructs a lung organ model retaining COPD pathological characteristics by optimizing tissue treatment, cell separation and three-dimensional culture conditions. The method comprises the following specific steps: acquiring fresh surgical resected lung tissues of a COPD patient; primary lung epithelial cells are obtained by combining collagenase IV digestion with cell filtration and lung interstitial cell separation; the method comprises the following steps: culturing cells by a matrigel embedding method, and culturing for 10 days by utilizing an amplification culture medium to form an organ-like structure; and then switching to a differential culture medium and inducing for 7 days to realize functional differentiation of the airway epithelial cells and the pulmonary alveolar cells. According to the method, the construction efficiency and stability of the organoid are remarkably improved, the constructed model can simulate the COPD pathological microenvironment, and the method is suitable for disease mechanism research, drug screening and individualized treatment evaluation and has high reproducibility and clinical transformation potential.

A system and method to facilitate the analysis of long-term scalp EEG recordings and the investigation of underlying epileptogenicity. Pathological high frequency oscillations are identified and extracted from the EEG recordings and electrophysiological source imaging is used to reconstruct cortical activity, which can be used as an aid in surgical resection for the treatment of epilepsy.

The invention belongs to the mass spectrum technology, and particularly provides a mass spectrum data analysis method and system based on multi-mode perception and intelligent prediction.The analysis method comprises the steps that A1, in the operation, a direct ionization mass spectrometer is used for scanning the surface of an excision cavity, and a metabolite concentration vector is obtained; performing full-field scanning to obtain optical characteristic data; collecting intraoperative image data; a2, performing spatial registration on the obtained multi-modal data, inputting mass spectrum point data into a pre-training model to obtain a pathological state probability, and taking the pathological state probability as anchor point data; a3, performing fusion model adjustment by taking the optical data and the intraoperative image as main input and taking the anchor pathological state as a training label, and outputting a full-field pathological state probability graph; and A4, according to the pathological state probability graph, dividing an excision cavity into a plurality of level areas according to a preset threshold value, overlapping and displaying information of the level areas in a surgical field, and guiding surgical excision. The invention has the advantages of accurate tumor excision and the like.

The present application relates to the technical field of tumor biology, and specifically discloses a human malignant giant cell tumor of bone cell line and application thereof, the human malignant giant cell tumor of bone cell line is preserved on April 9, 2025, the preservation address is China Center for Type Culture Collection, located in Wuhan University in Wuhan, Hubei Province, and the preservation number is CCTCC NO:C202539.The human malignant giant cell tumor of bone cell line of the present application is from the tumor tissue after surgical resection of a Chinese malignant giant cell tumor of bone patient, and is suitable as cell material for developing malignant giant cell tumor of bone related immunotherapy, diagnosis and drug development.The cell line of the present application contains H3F3A G34W mutation, and has high sensitivity and specificity in the diagnosis of malignant giant cell tumor of bone.This cell line can be used as a tool cell for researching target drugs with H3F3A as a target, provides a cell model for Chinese malignant giant cell tumor of bone research, and provides an experimental platform for mechanism research of malignant giant cell tumor of bone.

The present invention provides a multifunctional preoperative precise locator suitable for multiple organs, comprising a guiding system and a positioning system. The guiding system includes a guiding needle, a guiding needle handle, scale lines, rubber limiters, sharp needle cores, and blunt needle cores. The present invention enhances the safety and ease of operation of preoperative localization of small nodules in various organs, broadens the range of guidance devices for preoperative localization: ultrasound, CT, PET / CT, and MRI can all be used, significantly improves the accuracy of localization, can precisely guide the surgical resection range, and maximizes the preservation of residual anatomical structures and functions of organs in patients.

The invention relates to the field of confocal microendoscopes, and discloses a focus boundary joint positioning method, device, medium and equipment, firstly, macroscopic screening is performed by using a white light endoscope to obtain an optimal observation angle and an optimal working distance of a focus, then, a target scanning path of a confocal microendoscope probe under the optimal observation angle and the optimal working distance is established, and finally, the focus boundary joint positioning is performed. Then the confocal microendoscope probe is guided to carry out microscopic scanning along the target scanning path, microscopic mutation point information is obtained, finally boundary fusion is carried out on the macroscopic focus boundary and the microscopic mutation points through an algorithm, rapid and accurate positioning of the suspicious focus boundary is achieved, the accuracy of focus boundary recognition is improved, and therefore the surgical resection effect is improved, and the surgical resection rate is increased. The patient prognosis is improved.

Individualized neoantigen vaccines, as well as methods for their use in subjects to treat non-small cell lung cancer (NSCLC) are provided. In some embodiments, individualized neoantigen vaccines are used with an immune checkpoint inhibitor to treat a resectable NSCLC tumor after surgical resection. Prior to surgical resection, in some embodiments, the subject is administered a neoadjuvant therapy comprising an immune checkpoint inhibitor and chemotherapy.